Alessandro Boaro1,2, Vasileios K Kavouridis3,4, Francesca Siddi1,2, Elisabetta Mezzalira1,2, Maya Harary1,2,5, J Bryan Iorgulescu1,2,6,7, David A Reardon2,6, Timothy R Smith1,2. 1. Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, 60 Fenwood Rd., Boston, MA, , 02115, USA. 2. Harvard Medical School, Boston, MA, USA. 3. Computational Neuroscience Outcomes Center, Department of Neurosurgery, Brigham and Women's Hospital, 60 Fenwood Rd., Boston, MA, , 02115, USA. vkavouridis@bwh.harvard.edu. 4. Department of Neurosurgery, St. Olavs Hospital, Trondheim, Norway. vkavouridis@bwh.harvard.edu. 5. Department of Neurosurgery, University of California Los Angeles, Los Angeles, CA, USA. 6. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. 7. Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
Abstract
BACKGROUND: Butterfly glioblastomas (bGBMs) are grade IV gliomas that infiltrate the corpus callosum and spread to bilateral cerebral hemispheres. Due to the rarity of cases, there is a dearth of information in existing literature. Herein, we evaluate clinical and genetic characteristics, associated predictors, and survival outcomes in an institutional series and compare them to a national cohort. METHODS: We identified all adult patients with bGBM treated at Brigham & Women's Hospital (2008-2018). The National Cancer Database (NCDB) was also queried for bGBM patients. Survival was analyzed with Kaplan-Meier methods, and Cox models were built to assess for predictive factors. RESULTS: Of 993 glioblastoma patients, 62 cases (6.2%) of bGBM were identified. Craniotomy for resection was attempted in 26 patients (41.9%), with a median volumetric extent of resection (vEOR) of 72.3% (95% confidence interval [95%CI] 58.3-82.1). The IDH1 R132H mutation was detected in two patients (3.2%), and MGMT promoter was methylated in 55.5% of the assessed cases. In multivariable regression, factors predictive of longer OS were increased vEOR, MGMT promoter methylation, and receipt of adjuvant therapy. Median OS for the resected cases was 11.5 months (95%CI 7.7-18.8) vs. 6.3 (95%CI 5.1-8.9) for the biopsied. Of 21,353 GBMs, 719 (3.37%) bGBM patients were identified in the NCDB. Resection was more likely to be pursued in recent years, and GTR was independently associated with prolonged OS (p < 0.01). CONCLUSION: Surgical resection followed by adjuvant chemoradiation is associated with significant survival gains and should be pursued in carefully selected bGBM patients.
BACKGROUND: Butterfly glioblastomas (bGBMs) are grade IV gliomas that infiltrate the corpus callosum and spread to bilateral cerebral hemispheres. Due to the rarity of cases, there is a dearth of information in existing literature. Herein, we evaluate clinical and genetic characteristics, associated predictors, and survival outcomes in an institutional series and compare them to a national cohort. METHODS: We identified all adult patients with bGBM treated at Brigham & Women's Hospital (2008-2018). The National Cancer Database (NCDB) was also queried for bGBM patients. Survival was analyzed with Kaplan-Meier methods, and Cox models were built to assess for predictive factors. RESULTS: Of 993 glioblastomapatients, 62 cases (6.2%) of bGBM were identified. Craniotomy for resection was attempted in 26 patients (41.9%), with a median volumetric extent of resection (vEOR) of 72.3% (95% confidence interval [95%CI] 58.3-82.1). The IDH1R132H mutation was detected in two patients (3.2%), and MGMT promoter was methylated in 55.5% of the assessed cases. In multivariable regression, factors predictive of longer OS were increased vEOR, MGMT promoter methylation, and receipt of adjuvant therapy. Median OS for the resected cases was 11.5 months (95%CI 7.7-18.8) vs. 6.3 (95%CI 5.1-8.9) for the biopsied. Of 21,353 GBMs, 719 (3.37%) bGBM patients were identified in the NCDB. Resection was more likely to be pursued in recent years, and GTR was independently associated with prolonged OS (p < 0.01). CONCLUSION: Surgical resection followed by adjuvant chemoradiation is associated with significant survival gains and should be pursued in carefully selected bGBM patients.
Entities:
Keywords:
Butterfly glioblastoma; Corpus callosum; Extent of resection; Prognosis
Authors: Kristine Dziurzynski; David Blas-Boria; Dima Suki; Daniel P Cahill; Sujit S Prabhu; Vinay Puduvalli; Nicholas Levine Journal: J Neurooncol Date: 2012-07-18 Impact factor: 4.130
Authors: Daniel J Boffa; Joshua E Rosen; Katherine Mallin; Ashley Loomis; Greer Gay; Bryan Palis; Kathleen Thoburn; Donna Gress; Daniel P McKellar; Lawrence N Shulman; Matthew A Facktor; David P Winchester Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 31.777
Authors: Joshua D Burks; Phillip A Bonney; Andrew K Conner; Chad A Glenn; Robert G Briggs; James D Battiste; Tressie McCoy; Daniel L O'Donoghue; Dee H Wu; Michael E Sughrue Journal: J Neurosurg Date: 2016-09-16 Impact factor: 5.408
Authors: K Kallenberg; T Goldmann; J Menke; H Strik; H C Bock; F Stockhammer; J H Buhk; J Frahm; P Dechent; M Knauth Journal: J Neurooncol Date: 2013-01-24 Impact factor: 4.130
Authors: Paolo Palmisciano; Gianluca Ferini; Gina Watanabe; Christian Ogasawara; Emal Lesha; Othman Bin-Alamer; Giuseppe E Umana; Kenny Yu; Aaron A Cohen-Gadol; Tarek Y El Ahmadieh; Ali S Haider Journal: Cancers (Basel) Date: 2022-05-19 Impact factor: 6.575